Allogeneic Stem Cell Transplant with AlphaBeta T Cell and CD19 B Cell Depletion for Children and Young Adults with Leukemia and Lymphoma

What this Trial Is About

Researchers are evaluating the safety, effectiveness, and practical use of removing alphabeta CD3 T-cells and CD19 B-cells in stem cell transplants for patients with several blood cancers, including acute lymphocytic leukemia, acute myeloid leukemia, juvenile myelomonocytic leukemia, high-risk myelodysplastic syndrome, chronic myeloid leukemia, and lymphoma. This Phase 2 study focuses on patients aged 6 months to 39 years undergoing allogeneic stem cell transplantation. Participants receive stem cell transplants processed with the Miltenyi CliniMACS Prodigy system, which depletes alphabeta CD3 T-cells and CD19 B-cells from the donor graft. This specialized transplant is studied to assess its impact on transplant outcomes and complications. Throughout the study, researchers will monitor participants for the occurrence of acute graft versus host disease within 100 days after transplant. Additional outcomes include survival rates over two years, success of stem cell engraftment, and the incidence of viral infections and post-transplant lymphoproliferative disorder over the first year. Participants will be followed closely with clinical assessments and laboratory tests to track these outcomes until at least two years post-transplant.

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases